Unrelated Donor Transplant Versus Immune Therapy in Pediatric Severe Aplastic Anemia

• ClinicalTrials.gov Identifier: NCT02845596
• Recruitment Status: Active, not recruiting
• First Posted: July 27, 2016
• Last Update Posted: April 7, 2023
• Sponsor: Michael Pulsipher, MD
• Information provided by (Responsible Party): Michael Pulsipher, MD, Children's Hospital Los Angeles

Study Description

Brief Summary:

The purpose of this study is to determine the feasibility of comparing outcomes of patients treated de novo with immunosuppressive therapy (IST) versus matched unrelated donor (MUD) hematopoietic stem cell transplant (HSCT) for pediatric acquired severe aplastic anemia.

Condition or disease	Intervention/treatment	Phase
Severe Aplastic Anemia	Drug: cyclosporine; Procedure: Matched Unrelated Donor Hematopoietic Stem Cell Transplant; Drug: horse anti-thymocyte globulin (ATG); Drug: rabbit anti-thymocyte globulin (ATG); Drug: methotrexate; Drug: fludarabine; Drug: cyclophosphamide; Radiation: low-dose total body irradiation (TBI); Procedure: Immunosuppressive Therapy (IST)	Not Applicable

Detailed Description:

A major challenge in treating pediatric Severe Aplastic Anemia (SAA) is the determination of best primary therapy for patients who lack a fully matched related donor for HSCT. Good survival outcomes have been seen with IST, but initial and late failures, CSA dependence, persistent cytopenias and secondary Myelodysplastic Syndrome (MDS) / Acute Myeloid Leukemia (AML) in a portion of patients leave considerable room for improvement. MUD HSCT survival in SAA has markedly improved, but a direct comparison of this approach with IST is necessary to determine whether this approach is feasible and will lead to better Event Free Survival. This trial will address the feasibility of randomization, test whether patients can be evaluated in a timely fashion and safely begin therapy with MUD HSCT or IST, and give a preliminary assessment of the safety of up-front MUD HSCT. If successful, this trial will lead to a future prospective trial comparing directly IST to MUD HSCT in this disease.

Study Design

• Study Type: Interventional (Clinical Trial)
• Estimated Enrollment: 40 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: None (Open Label)
• Primary Purpose: Other
• Official Title: Unrelated Donor Transplant Versus Immune Therapy in Pediatric Severe Aplastic Anemia
• Study Start Date: August 2016
• Estimated Primary Completion Date: August 2023
• Estimated Study Completion Date: August 2023

Arms and Interventions

Arm	Intervention/treatment
Active Comparator: Immunosuppressive Therapy; Patient will receive standard immunosuppressive therapy combination of drugs: horse anti-thymocyte globulin (ATG) and cyclosporine.	Drug: cyclosporine; cyclosporine; Drug: horse anti-thymocyte globulin (ATG); horse anti-thymocyte globulin (ATG); Other Name: ATGAM; Procedure: Immunosuppressive Therapy (IST); Immunosuppressive Therapy (IST)
Active Comparator: Matched Unrelated Stem Cell Transplant; Patient will under go matched unrelated donor transplant of hematopoietic stem cells as their therapy using fludarabine, cyclophosphamide, rabbit anti-thymocyte globulin (ATG), and low-dose total body irradiation (TBI) as preparative regimen and cyclosporine and methotrexate for graft versus host disease (GVHD) prevention.	Drug: cyclosporine; cyclosporine; Procedure: Matched Unrelated Donor Hematopoietic Stem Cell Transplant; Matched Unrelated Donor (MUD) Hematopoietic Stem Cell Transplantation (HSCT); Drug: rabbit anti-thymocyte globulin (ATG); rabbit anti-thymocyte globulin (ATG); Other Name: Thymoglobulin; Drug: methotrexate; methotrexate; Drug: fludarabine; fludarabine; Drug: cyclophosphamide; cyclophosphamide; Radiation: low-dose total body irradiation (TBI); low-dose total body irradiation (TBI)

Outcome Measures

Primary Outcome Measures :

1. Percentage of patients randomized to HSCT that actually complete HSCT [ Time Frame: 4 years ]
   Feasibility of comparing outcomes of patients treated de novo with IST versus matched unrelated donor HSCT for pediatric acquired severe aplastic anemia as defined by percentage of patients randomized to HSCT that actually complete HSCT.

Secondary Outcome Measures :

1. Time from screening consent to randomization [ Time Frame: 4 years ]
   To measure the time from screening consent and randomization of patients to initiation of the preparative regimen of those randomized to HSCT.
2. Number of patients that fail to receive their primary assigned therapy (HSCT or IST). [ Time Frame: 4 years ]
   Number of patients fail to receive their primary assigned therapy (HSCT or IST).
3. Reasons why patients fail to receive their primary assigned therapy (HSCT or IST). [ Time Frame: 4 years ]
   Reasons why patients fail to receive their primary assigned therapy (HSCT or IST).
4. Treatment-related mortality at one year from randomization in both arms [ Time Frame: 1 Year ]
   Number of deaths that are treatment related
5. Overall Survival at one year from randomization in both arms [ Time Frame: 1 Year ]
   percentage of enrolled patients living at 1 year post randomization
6. Time from randomization to neutrophil recovery in both arms [ Time Frame: 4 years ]
   Time from randomization to neutrophil recovery in both arms
7. Time from randomization to platelet recovery in both arms [ Time Frame: 4 years ]
   Time from randomization to platelet recovery in both arms
8. Time from randomization to red blood cell recovery in both arms [ Time Frame: 4 years ]
   Time from randomization to red blood cell recovery in both arms
9. Time from randomization to cessation of immune suppression recovery in both arms [ Time Frame: 4 years ]
   Time from randomization to cessation of immune suppression recovery in both arms
10. Rates of primary and secondary graft rejection in the MUD HSCT arm [ Time Frame: 4 years ]
    Rates of primary and secondary graft rejection in the MUD HSCT arm
11. Rates of grade II-IV and III-IV acute GVHD, and extensive chronic GVHD in the MUD HSCT arm [ Time Frame: 4 years ]
    Rates of grade II-IV and III-IV acute GVHD, and extensive chronic GVHD in the MUD HSCT arm
12. Rates of IST response [ Time Frame: 4 years ]
    Rates of IST response
13. Rates of IST relapse [ Time Frame: 4 years ]
    Rates of IST relapse
14. Rates of secondary MDS or AML in both treatment arms. [ Time Frame: 4 years ]
    Rates of secondary MDS or AML in both treatment arms.
15. Rates of other secondary malignancies in both treatment arms. [ Time Frame: 4 years ]
    Rates of other secondary malignancies in both treatment arms.
16. Development of symptomatic PNH in both treatment arms. [ Time Frame: 4 years ]
    Development of symptomatic PNH in both treatment arms.
17. Incidence of significant infection in both treatment arms [ Time Frame: 4 years ]
    Incidence of significant infection in both treatment arms
18. Time to immune reconstitution in the HSCT arm [ Time Frame: 4 years ]
    Time to immune reconstitution in the HSCT arm

Eligibility Criteria

• Ages Eligible for Study: up to 25 Years (Child, Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

1. Confirmed diagnosis of idiopathic SAA, defined as:

   • Bone marrow cellularity <25%, or <30% hematopoietic cells.
   • Two out of three of the following (in peripheral blood): neutrophils <0.5 x109/L, platelets <20 x109/L, reticulocyte count <60 x109/L with hemoglobin <8g/dL.
2. Age ≤25 years old.
3. No suitable fully matched related donor available (minimum 6/6 match for Human Leukocyte antigen (HLA) -A and B at intermediate or high resolution and DRB1 at high resolution using DNA based typing).
4. At least two unrelated donors noted on National Marrow Donor Program (NMDP) search who are well matched (9/10 or 10/10 for HLA-A, B, C, DRB1, and DQB1 using high resolution).
5. Signed informed consent for the randomized trial by patient and/or legal guardian.
6. Adequate organ function defined as in the judgment of the investigator, there is not irreversible organ damage that would preclude the patient from meeting the organ function inclusion criteria for HSCT listed in section 2.3.4 by the intended time of HSCT (6-8 weeks after randomization) or preclude patients from receiving horse ATG.

Exclusion Criteria:

1. Inherited bone marrow failure syndromes (IBMFS). The diagnosis of Fanconi anemia must be excluded by diepoxybutane (DEB) or equivalent testing on peripheral blood or marrow. Telomere length testing should be sent on all patients to exclude Dyskeratosis congenita, but if results are delayed or unavailable and there are no clinical manifestations of DC, patients may enroll. If patients have clinical characteristics suspicious for Shwachman Diamond syndrome, this syndrome must be excluded by pancreatic isoamylase testing or gene mutation analysis. Note: pancreatic isoamylase testing is not accurate in children less than 3 years.
2. Clonal cytogenetic abnormalities or fluorescence In Situ Hybridization (FISH) pattern consistent with pre-myelodysplastic syndrome (pre-MDS) or MDS on marrow examination (see section 4.2.3.1 for details of the required MDS FISH panel).
3. Known severe allergy to horse ATG.
4. Prior allogeneic stem cell transplant.
5. Prior solid organ transplant.
6. Infection with human immunodeficiency virus (HIV).
7. Active Hepatitis B or C. This should be excluded in patients where there is clinical suspicion of hepatitis (e.g. elevated LFTs).
8. Female patients who are pregnant or breast-feeding.
9. Prior malignancies except resected basal cell carcinoma or treated cervical carcinoma in situ.

Contacts and Locations

Locations

United States, California

Children's Hospital Los Angeles

Los Angeles, California, United States, 90027

Stanford Lucile Packard Children's Hospital

Palo Alto, California, United States, 94304

UCSF

San Francisco, California, United States, 94123

United States, Colorado

Children's Hospital Colorado

Aurora, Colorado, United States, 80045

United States, Massachusetts

Boston Children's Hospital

Boston, Massachusetts, United States, 02115

United States, New Jersey

Hackensack University Medical Center

Hackensack, New Jersey, United States, 07601

United States, New York

Cohen Children's Medical Center

Queens, New York, United States, 11040

United States, Ohio

Cleveland Clinic

Cleveland, Ohio, United States, 44195

United States, Pennsylvania

Children's Hospital of Philadelphia

Philadelphia, Pennsylvania, United States, 19104

United States, Texas

UT Southwestern Medical Center

Dallas, Texas, United States, 75390

Texas Children's Hospital

Houston, Texas, United States, 77030

United States, Washington

Fred Hutchinson Cancer Research Center

Seattle, Washington, United States, 98109

United States, Wisconsin

University of Wisconsin

Madison, Wisconsin, United States, 53792

Sponsors and Collaborators

Michael Pulsipher, MD

Investigators

• Study Chair: Michael Pulsipher, MD; Children's Hospital Los Angeles
• Study Chair: David A Williams, MD; Boston's Childrens Hospital

More Information

• Responsible Party: Michael Pulsipher, MD, Principal Investigator, Children's Hospital Los Angeles
• ClinicalTrials.gov Identifier: NCT02845596
• Other Study ID Numbers: TransIT NMD 1601
• First Posted: July 27, 2016
• Last Update Posted: April 7, 2023
• Last Verified: April 2023

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: Undecided

Additional relevant MeSH terms:

Anemia; Anemia, Aplastic; Hematologic Diseases; Bone Marrow Failure Disorders; Bone Marrow Diseases; Cyclosporine; Cyclophosphamide; Methotrexate; Fludarabine; Cyclosporins; Thymoglobulin; Antilymphocyte Serum; Immunosuppressive Agents; Immunologic Factors; Physiological Effects of Drugs; Antirheumatic Agents; Antineoplastic Agents, Alkylating; Alkylating Agents; Molecular Mechanisms of Pharmacological Action; Antineoplastic Agents; Myeloablative Agonists; Abortifacient Agents, Nonsteroidal; Abortifacient Agents; Reproductive Control Agents; Antimetabolites, Antineoplastic; Antimetabolites; Dermatologic Agents; Enzyme Inhibitors; Folic Acid Antagonists; Nucleic Acid Synthesis Inhibitors